Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk.

High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk.

Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells.

Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk.

Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion.

Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy.

A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker.

Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A

Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India.

Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk.

Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring.

Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry.

Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients.

Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring.

AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research.

This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk.

High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring.

Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival.

Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer.

This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care.

Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring.